Sarepta, Biotech’s Regulatory Go-Getter, Signs Standout Rare Disease Deal

Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead Pharmaceuticals on RNAi-based medicines.